Sucralfin Special Precautions

Duodenal ulcer is a chronic recurrent disease; successful therapy with sucralfate should not be expected to alter the post-healing frequency of recurrence or the severity of duodenal ulcer.
Renal impairment: Sucralfate under acid conditions can release aluminium ions that may be absorbed systemically. Aluminium toxicity in patients with normal renal function receiving sucralfate would not be expected, but seizures, muscle weakness, bone pain, and severe aluminium encephalopathy have been reported in patients with end-stage renal disease requiring dialysis. Sucralfate should be used with caution in patients with renal impairment, especially if other aluminium-containing agents are also taken, and such patients should be monitored for signs of aluminium toxicity.
Pediatric: Safety and efficacy of sucralfate have not been established in children.
Pregnancy, Fertility and Lactation: There are no adequate and controlled studies to date using sucralfate in pregnant women and the drugs should be used during pregnancy only when clearly needed. Effects of sucralfate on fertility in humans are not known. It is not known if sucralfate is distributed into milk; the drug should be used with caution in nursing women.